TG Therapeutics Inc (TGTX) Company Profile & Statistics

TG Therapeutics Inc
TGTX
(Nasdaq - US)
Closed
29.52
-1.33 (-4.31%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
30.51
High
30.97
Low
28.92

About TG Therapeutics Inc

CEO

Michael S. Weiss

Headquarters

3020 carrington mill blvd, suite 475

morrisville, ny 27560, united states

Auditor

KPMG LLP

Employees

264

Share Holders

214

Website

www.tgtherapeutics.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

TG Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	4.59B
Enterprise Value	4.61B
Enterprise Value/EBITDA (ttm)	46.35
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	23.93
Price to Sales (ttm)	17.37
Price to Cash (ytd)	337.89

Profitability

Gross Margin (ttm)	90.04%
Operating Margin (ttm)	-5.42%
Profit Margin (ttm)	7.10%
Return on Equity (ttm)	-8.32%
Return on Invested Capital (ttm)	36.04%
Return on Assets (ttm)	-3.40%

Income Statement

Revenue (ttm)	346.73M
Revenue Per Share (ttm)	2.24
Gross Profit (ttm)	321.62M
EBITDA (ttm)³	99.55M
Net Income Avi to Common (ttm)	95.69M
Diluted EPS (ttm)	-0.10

Share Statistics

Beta (5Y Monthly)	2.19
52-Week Change	130.23%
S&P500 52-Week Change	29.10%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	154.82M
Dividend Yield	0.00%
Float ⁴	139.32M
% Held by Insiders	10.50%
% Held by Institutions	58.58%

Balance Sheet

Total Cash (mrq)	217.25M
Total Cash Per Share (mrq)	1.40
Total Debt (mrq)	102.54M
Total Debt/Equity (mrq)	57.75%
Current Ratio (mrq)	3.58%
Quick Ratio (mrq)	3.91%
Book Value Per Share (mrq)	1.15

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.02
Free Cash Flow (ytd)	-2.67M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TG Therapeutics Inc

Trade With A Regulated Broker